

Lupin Limited (LUPN.NS - INR 1420.45) Buy

Operating Results

Delivers, potential remains

Saion Mukherjee 91.22.4037.4184 saion.mukherjee@nomura.com Mumbai	Avinash Ghalke 91.22.4037.4197 avinash.ghalke@nomura.com Mumbai
----------------------------------------------------------------------------	--------------------------------------------------------------------------

Investment Conclusion

□ LPC Q3FY10 results were in line with our expectations. Post the 9mFY10 performance we have marginally reduced our EPS ests. We believe LPC business is structurally strong and can sustain revenue growth of 25-30% as guided by management. Generic product approvals and pick-up in brand sales in the US are key to growth going forward and can present significant surprise to the current estimates. We reset our target price to INR 1707/sh as we value the base business ex one-offs at 17x FY12 and add INR 50/sh for product-specific opportunities. Maintain BUY.

FY Mar	2009A	2010E	2011E	2012E			
Currency INR	Actual	Old	New	Old	New	Old	New
Revenue (bn)	38.3	47.2	47.0	52.5	53.7	60.9	62.2
Op. Profit (bn)	7.3	9.9	9.3	11.1	11.3	13.2	13.1
Rec. Prof. (bn)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income (bn)	5.0	6.6	6.1	7.2	7.3	8.9	8.7
EPS	56.5	74.6	68.7	81.6	81.9	100.4	97.5
EV/EBITDA	18.3	N/A	14.4	N/A	11.8	N/A	9.9
P/E	25.1	19.0	20.7	17.4	17.3	14.1	14.6

Summary

□ Q3 FY10 highlights: a) Net sales at INR12.5bn, 31% increase YoY (our est INR12.2bn); b) EBITDA at INR2.6bn, 49% increase YoY (our est. INR2.37bn); c) Net profit at INR1.6bn, 38% increase YoY in line with our est.

Market Data

Market Cap	126308
Market cap (US\$ mn)	2725
Shares Outstanding (mn)	88.9
6-mo daily T/O (US\$ mn)	1
Free Float (%)	49.56
Foreign Shareholding (%)	13.76

Financial Summary

Proj 5-Yr EPS Grth (%)	19.0
RoE (%)	37.1
Net Debt to Equity (%)	56.8


Stock Rating

Target Price

New: Buy	New: INR 1707.00
Old: Buy	Old: INR 1506.00

Sector View: Bullish

Stock Overview



Reuters	LUPN.NS
Bloomberg	LPC IN
ADR	
Performance	1M 3M 12M
Absolute %	-2.9 15.2 153.1
Rel. Market %	2.6 11.1 36.5
Rel. Sector %	N/A N/A N/A

52 Week Range 1524.00 - 565.10

LPC Q3FY10 results were in line with our expectations. LPC recorded sales of INR12.5bn, 31% growth YoY higher than our estimate of INR12.2bn with positive surprise in the API business. EBITDA margin improved 260bps YoY to 20.9% ahead of our expectation of 19.4%. However, the higher than expected tax rate resulted in net profit of INR1.6bn, in line with our expectation.

Post the 9mFY10 performance we have made marginal changes in our model. As a result, our earnings estimates for FY11-12 are reduced by 0-3%. FY10 earnings cut by 8% on back of lower EBITDA margin estimate.

LPC has re-rated significantly from 8x a year back to 17.5x currently. Post the FDA clearance for the Mandideep facility we expect LPC to trade between 16x and 18x one yr fwd EPS, which we believe is a fair valuation range for front-line generic companies. From here on we expect the stock appreciation to be linked primarily to earnings growth with limited scope for further re-rating.

We believe LPC business is structurally strong and can sustain revenue growth of 25-30% as guided by management. The guidance is higher than our expectation of 14-16%. Outperformance to the current expectation will largely be driven by the US market. Generic product approvals and a pick-up in brand sales in the US hold the potential to present positive surprise. Given limited clarity on approval timing and early days for the branded business (ex Suprax), we haven't built the potential upside into our estimates. The quarterly profit for LPC has now settled at INR1.6bn and any further increase in the profit run rate is contingent upon product approvals in the US, in our view.

**ANY AUTHORS NAMED ON THIS REPORT ARE RESEARCH ANALYSTS UNLESS OTHERWISE INDICATED.
PLEASE SEE ANALYST(S) CERTIFICATION(S) ON PAGE 6 AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 7**

Therefore, we believe the stock will await some clarity on growth to emerge before it makes the next move up. In the near term the key catalyst will be approval of Lotrel, in our view. Over the next 3-4 quarters execution of the branded business in the US will be the key driver for the stock in our view. Pick up in brand sales for Antara and Allernaze (expected to be launched in Q1FY11) and strategy to further scale up the business to counter eventual genericisation of Suprax and Antara will be key, in our view.

We reset our target price to INR1707/sh as we value the base business ex one offs at 17x FY12 and add INR50/sh for product-specific opportunities (unchanged). Our valuation of the base business is in line with other front line generic companies. The key risks to our call are a) delay in product approvals in the US; b) execution slippage in the branded business and c) slowdown in Indian domestic formulation growth.

Figure 1: Qtrly P&L

(in INRmn)	3QFY09	2QFY10	3QFY10	YoY (%)	3QFY10E
Gross Sales	9,719	11,216	12,627	30%	12,303
Excise Duty	100	69	72	-28%	69
Net Sales	9,618	11,147	12,554	31%	12,234
Other Operating income	218	511	154	-30%	200
Total operating income	9,837	11,658	12,708	29%	12,434
Material costs	3,858	5,014	5,122	33%	5,220
Staff costs	1,205	1,405	1,528	27%	1,405
Other expenditure	3,016	3,088	3,441	14%	3,436
Total Expenditure	8,079	9,507	10,090	25%	10,061
EBITDA	1,758	2,150	2,618	49%	2,374
EBITDA margins (% of net sales)	18.3%	19.3%	20.9%	14%	19.4%
Other income	3	30	2	-47%	50
Interest	146	91	109	-25%	125
Depreciation	219	242	358	63%	336
PBT	1,396	1,847	2,152	54%	1,963
Tax	219	200	504	131%	314
Tax rate	15.6%	10.8%	23.4%		16.0%
MI + Share of associates	13	43	42		43
PAT	1,165	1,603	1,606	38%	1,606
(% of net sales)					
Material costs	40.1%	45.0%	40.8%	69 bps	42.7%
Staff costs	12.5%	12.6%	12.2%	-36 bps	11.5%
Other Expenditure	31.4%	27.7%	27.4%	-394 bps	28.1%
EBITDA Margin	18.3%	19.3%	20.9%	257 bps	19.4%

Source: Company data, Nomura estimates

Key Highlights

Figure 2: Net sales breakdown

INRmn	3QFY09	2QFY10	3QFY10	% Chg YoY
Advanced market formulations	4,754	4,814	6,426	35%
US	3,141	3,348	4,299	37%
Europe	295	183	638	116%
Japan	1,319	1,283	1,489	13%
India formulations	2,838	3,467	3,446	21%
Other formulations	161	922	768	376%
API	1,866	1,944	1,914	3%
Net sales	9,619	11,147	12,554	31%

Source: Company data, Nomura estimates

US

US revenues at INR4.3bn, 37% growth YoY was largely in line with our expectation. The branded business increased to INR1.8bn from INR1.07bn in the previous quarter on back of incorporation of Antara sales and seasonal increase in Suprax sales. As per management, the decline in Antara prescriptions has been arrested and the current run rate suggest annual turnover of US\$60-70m from Antara. Based on the citizen petition filed by Lupin for Suprax and competitive intelligence gathered, the company doesn't expect any generic competition in Suprax in the near term. We believe over time in FY11 there can be generic competition at least in the single strength Suprax. With launch of Antara, the brand business in the US accounts for 43% of the US formulation revenues.

Lupin has filed for 15 ANDAs so far in FY10 and expects 25-30 filings in FY10. The filings will be bunched up in Q4 as was the case last year. The pipeline of outstanding ANDAs (for approval) has increased from 44 a year ago to 70 currently. LPC expects to launch 10 new products in FY11 with 2-3 niche low competition launches. The company expects approval and launch of Lotrel in the near term and two additional products with brand sales of US\$500m in FY11. Given the pipeline the product launches are expected to accelerate in FY12.

Japan

Japan recorded revenue of INR1.5bn, 13% increase YoY. In local currency term the growth is 9%. The growth is likely to be muted in the near term primarily on account of lack of big launches and some pricing pressure. Though the top line growth is expected to be moderate, management expects margins to expand. Lupin is well seeded in Japan to address the opportunity as and when the generic market expands.

India

India continues to demonstrate strong growth. In Q3FY10, LPC recorded growth of 21% in net sales. For 9mFY10, sales growth is at 20%. The growth in the Indian market is driven primarily by new product introductions. LPC has been relatively successful with new introductions and products launched over the last 2 years contribute 9% of the domestic sales. As per ORG IMS data, product launches in 2008 and 2009 contributed almost 65% of the growth. Management expects to sustain growth rate of 20% in the near future.

EBITDA margin expands

LPC reported EBITDA margin of 19.5% (adjusted for other income), highest in the last 11 quarters. Improving product mix with increasing revenues from the branded business has resulted in the increase. Management expects to deliver at least 50bps improvement in EBITDA margin YoY. Management has indicated an outstanding hedging position of US\$491m - this would help mitigate margin risk in the eventuality of INR appreciation.

Outlook- Growth would largely depend on the US over the next 12 months

Management expects revenue growth of 25-30% in FY11. With India growth at 20% and Japan in low teens, we believe achieving the growth will be largely contingent upon product approvals and launches in the US and ramp up in brand sales in the US. Products with low competition like Lotrel will be key to achieve the growth target in our view. At this stage we aren't building in potential upside from such launches and hence project growth of 14-16% over the next two years.

Changing our estimates marginally

We make changes in our earnings model to incorporate the performance so far in 9mFY09. Our sales estimates are revised upwards by 1-3% as we build in higher US brand and API sales. Core EBITDA margin is revised 0-2% for FY11-12 as we build in marginal cut in margin estimates. EBITDA estimates for FY10 are reduced by 8% on lower margin assumption. FY11-12 earning estimate stand reduced by 0-3% on back of higher depreciation relating to Antara.

Figure 3: Change in estimates


INRmn	Current estimates			Previous estimates			% Chg		
	FY10E	FY11E	FY12E	FY10E	FY11E	FY12E			
Total gross sales	47,036	53,717	62,229	46,749	52,234	60,539	1	3	3
Y-Y growth rate	23.0%	14.2%	15.8%	22.3%	11.7%	15.9%			
Core EBITDA	9,270	11,257	13,121	9,866	11,053	13,178	(6)	2	(0)
Margins	19.7%	21.0%	21.1%	21.1%	21.2%	21.8%			
Net profit	6,094	7,265	8,650	6,624	7,244	8,911	(8)	0	(3)
Y-Y growth rate	21.5%	19.2%	19.1%	32.1%	9.4%	23.0%			
EPS	68.7	81.9	97.5	74.6	81.6	100.4			

Source: Nomura estimates

Structurally strong- Maintain Buy

LPC has re-rated significantly from 8x a year back to 17.5x currently. Post the FDA clearance for the Mandideep facility we expect LPC to trade between 16x and 18x one yr fwd EPS which we believe is a fair valuation range for front-line generic companies. From here on we expect the stock appreciation to be linked primarily to earnings growth with limited scope for further re-rating. We believe LPC is well seeded in India, US and Japan to address the growth opportunities in these markets. India and US will be the near term growth drivers, in our view. From medium to long term perspective growth may accelerate in Japan as the generic market opens up and LPC being the largest Indian player operating in the market will address the opportunity as and when it arises, in our view.

Figure 4: Significant re-rating over the last one year



Source: Bloomberg, Nomura estimates

Management has guided for 25-30% growth in the near term, which compares to our estimate of 14-15%. The US market holds the key for upsides to our growth estimates. We believe management guidance is achievable on back of US approvals and strong execution in the brand business. Given limited clarity on approval timing and early days for the branded business (ex Suprax), we haven't built the potential upside in our estimates, but it remains a possibility.

Therefore, we believe the stock will await some clarity on growth to emerge before it makes the next move up. In the near term the key catalyst will be approval of Lotrel in our view. Over the next 3-4 quarters execution of the branded business in the US will be the key driver for the stock in our view. Pick up in brand sales of Antara and Allernaze (expected to be launched in Q1FY11) and strategy to further scale up the business to counter eventual genericisation of Suprax and Antara will be key, in our view.

We reset our target price to INR1707/sh as we value the base business ex one offs at 17x FY12 and add INR50/sh for product-specific opportunities (unchanged). Our valuation of the base business is in line with other front line generic companies. The key risks to our call are a) delay in product approvals in the US; b) execution slippage in the branded business and c) slowdown in Indian domestic formulation growth.

Figure 5: Change in 12m target price

INR/share	Current	Previous
Base business valuation	1,657	1,456
Product specific potential upside	50	50
Target price	1,707	1,506

Source: Nomura estimates

Figure 6: Income Statement

Year ended 31 Mar (INRmn)	FY08	FY09	FY10E	FY11E	FY12E
Gross sales	27,730	38,238	47,036	53,717	62,229
Other operating income	1,645	537	986	850	1,002
Excise duty	666	479	316	374	431
Net Sales	28,709	38,296	47,706	54,193	62,799
Operating expenses	22,417	31,016	38,436	42,936	49,678
Material costs	11,638	16,043	19,713	21,603	24,997
Other expenditure	9,233	12,655	15,246	17,334	20,083
R&D costs	1,546	2,318	3,477	3,999	4,599
Core EBITDA	6,291	7,279	9,270	11,257	13,121
Other income	132	160	100	130	200
Interest	374	499	467	534	534
Depreciation	647	880	1,258	1,746	1,970
PBT	5,402	6,060	7,645	9,107	10,817
Tax	1,318	983	1,376	1,639	1,947
PAT	4,084	5,077	6,269	7,468	8,870
Minority interest & prior period items	2	62	175	203	219
Net profits	4,083	5,015	6,094	7,265	8,650

Source: Company data, Nomura estimates

Figure 7: Balance Sheet

Year ended 31 Mar (INRmn)	FY08	FY09	FY10E	FY11E	FY12E
Current assets	20,441	23,478	26,682	30,369	37,670
Investments	58	216	216	216	216
Net fixed assets	11,125	14,252	20,824	24,359	25,740
Other non-current assets	1,872	3,174	3,174	3,174	3,174
Total assets	33,497	41,119	50,895	58,117	66,799
Current liabilities	6,019	11,504	13,116	14,340	15,900
Total Debt	12,029	12,233	11,870	11,870	11,870
Other liabilities	2,558	2,992	3,448	3,942	4,527
Total liabilities	20,606	26,728	28,434	30,152	32,296
Share capital	821	828	888	888	888
Reserves & surplus	11,976	13,420	21,318	26,794	33,315
Shareholders' funds	12,797	14,248	22,205	27,682	34,203
Minorities	95	143	256	283	300
Total equity & liabilities	33,497	41,119	50,895	58,117	66,799

Source: Company data, Nomura estimates

Figure 8: Cash Flow Statement

Cash Flow Statement	FY08	FY09	FY10E	FY11E	FY12E
Year ended 31 Mar (INRmn)					
Pre-tax profit	5,402	6,060	7,645	9,107	10,817
Depreciation	647	880	1,258	1,746	1,970
Tax paid	-1,090	-1,068	-1,185	-1,434	-1,703
Chg in working capital	-2,589	-1,739	270	-1,796	-2,288
Others	214	562	734	404	334
Cash flow from operations (a)	2,585	4,695	8,722	8,027	9,129
Capital expenditure	-5,065	-4,953	-7,784	-5,000	-3,000
Chg in investments and others	147	-143	100	130	200
Cash flow from investing (b)	-4,918	-5,096	-7,684	-4,870	-2,800
Free cash flow (a+b)	-2,333	-401	1,038	3,157	6,329
Equity raised/(repaid)	26	54	3,363	0	0
Debt raised/(repaid)	1,626	-246	-363	0	0
Dividend (incl. tax)	-477	-983	-1,235	-1,500	-1,788
Others	55	-388	-529	-709	-737
Cash flow from financing (c)	1,230	-1,563	1,237	-2,209	-2,525
Net chg in cash (a+b+c)	-1,103	-1,964	2,275	948	3,804

Source: Company data, Nomura estimates

Analyst Certification:

We, Saion Mukherjee and Avinash Ghalke, hereby certify (1) that the views expressed in this Company Note accurately reflect our personal views about any or all of the subject securities or issuers referred to in this Company Note, (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Company Note and (3) no part of our compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.


Company Description:

Lupin is the fifth-largest Indian generic pharmaceuticals company in terms of revenue. Key markets for Lupin include India, the US and Japan.

Important Disclosures:

Lupin Limited (LUPN.NS)**INR 1420.45 (29-Jan-2010)****Buy / Bullish**

Rating and Price Target Chart:



Currency=INR

Date	Closing Price	Rating	Price Target
16-Oct-09	1279.60		1506.00
16-Oct-09	1279.60	Buy	
23-Sep-09	1064.55		1251.00
23-Sep-09	1064.55	Buy	
02-Jun-09	817.20		1028.00

Date	Closing Price	Rating	Price Target
02-Jun-09	817.20	Buy	
02-Feb-09	565.15		919.00
02-Feb-09	565.15	Buy	
25-Nov-08	547.50		982.00
25-Nov-08	547.50	Buy	

FOR EXPLANATIONS OF RATINGS REFER TO THE STOCK RATING KEYS LOCATED ON THE PAGE FOLLOWING THE LAST PRICE CHART.

Valuation Methodology: Our 12-month price target of INR1,707/share is based on SOTP: a) base business valued at INR1,657, 17x FY12 and b) P4 pipeline valued at INR50/share.

Risks Which May Impede the Achievement of the Price Target: 1) Delay in product approvals in the US; 2) The entry of generic competition in Suprax and simultaneous failure of scale up the brand business with new launches; 3) Slowdown in domestic formulation business

Important Disclosures Continued:

Company Name	Ticker	Price	Price Date	Stock / Sector Rating
Lupin Limited	LUPN.NS	INR 1420.45	29-Jan-2010	Buy / Bullish

All share prices mentioned are closing prices unless otherwise stated.

ISSUER SPECIFIC REGULATORY DISCLOSURES**Online availability of research and additional conflict-of-interest disclosures:**

Nomura Japanese Equity Research is available electronically for clients in the US on NOMURA.COM, REUTERS, BLOOMBERG and THOMSON ONE ANALYTICS. For clients in Europe, Japan and elsewhere in Asia it is available on NOMURA.COM, REUTERS and BLOOMBERG.

Important disclosures may be accessed through the left hand side of the Nomura Disclosure web page <http://www.nomura.com/research> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email researchportal@nomura.co.uk for technical assistance.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities.

Distribution of Ratings:

Nomura Global Equity Research has 1724 companies under coverage.

41% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 42% of companies with this rating are investment banking clients of the Nomura Group*.

40% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 50% of companies with this rating are investment banking clients of the Nomura Group*.

19% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 8% of companies with this rating are investment banking clients of the Nomura Group*.

As at 30 September 2009.

*The Nomura Group as defined in the Disclaimer section at the end of this report.

Explanation of Nomura's equity research rating system in Europe, Middle East and Africa, US and Latin America for ratings published from 27 October 2008:

The rating system is a relative system indicating expected performance against a specific benchmark identified for each individual stock. Analysts may also indicate absolute upside to price target defined as (fair value - current price)/current price, subject to limited management discretion. In most cases, the fair value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as discounted cash flow or multiple analysis, etc.

Stocks:

- A rating of "1", or "**Buy**", indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months.
- A rating of "2", or "**Neutral**", indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months.
- A rating of "3", or "**Reduce**", indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months.
- A rating of "**RS-Rating Suspended**" indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the company.

Benchmarks are as follows: **United States/Europe:** Please see valuation methodologies for explanations of relevant benchmarks for stocks (accessible through the left hand side of the Nomura Disclosure web page: <http://www.nomura.com/research>); **Global Emerging Markets (ex-Asia):** MSCI Emerging Markets ex-Asia, unless otherwise stated in the valuation methodology.

Sectors:

A "**Bullish**" stance, indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months.

A "**Neutral**" stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months.

A "**Bearish**" stance, indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months.

Benchmarks are as follows: **United States:** S&P 500; **Europe:** Dow Jones STOXX® 600; **Global Emerging Markets (ex-Asia):** MSCI Emerging Markets ex-Asia.

Explanation of Nomura's equity research rating system for Asian companies under coverage ex Japan published from 30 October 2008 and in Japan from 6 January 2009:**Stocks:**

Stock recommendations are based on absolute valuation upside (downside), which is defined as (Price Target – Current Price) / Current Price, subject to limited management discretion. In most cases, the Price Target will equal the analyst's 12-month intrinsic valuation of the stock, based on an appropriate valuation methodology such as discounted cash flow, multiple analysis, etc.

- A rating of "1", or "**Buy**" recommendation indicates that potential upside is 15% or more.
- A rating of "2", or "**Neutral**" recommendation indicates that potential upside is less than 15% or downside is less than 5%.
- A rating of "3", or "**Reduce**" recommendation indicates that potential downside is 5% or more.
- A rating of "**RS**" or "**Rating Suspended**" indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company.
- Stocks labeled as "**Not rated**" or shown as "**No rating**" are not in Nomura's regular research coverage.

Sectors:

A "**Bullish**" rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation.

A "**Neutral**" rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation.

A "**Bearish**" rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation.

Explanation of Nomura's equity research rating system in Japan published prior to 6 January 2009 (and ratings in Europe, Middle East and Africa, US and Latin America published prior to 27 October 2008):

Stocks:

- A rating of "1", or "**Strong buy**", indicates that the analyst expects the stock to outperform the Benchmark by 15% or more over the next six months.
- A rating of "2", or "**Buy**", indicates that the analyst expects the stock to outperform the Benchmark by 5% or more but less than 15% over the next six months.
- A rating of "3", or "**Neutral**", indicates that the analyst expects the stock to either outperform or underperform the Benchmark by less than 5% over the next six months.
- A rating of "4", or "**Reduce**", indicates that the analyst expects the stock to underperform the Benchmark by 5% or more but less than 15% over the next six months.
- A rating of "5", or "**Sell**", indicates that the analyst expects the stock to underperform the Benchmark by 15% or more over the next six months.
- Stocks labeled "**Not rated**" or shown as "**No rating**" are not in Nomura's regular research coverage. Nomura might not publish additional research reports concerning this company, and it undertakes no obligation to update the analysis, estimates, projections, conclusions or other information contained herein.

Sectors:

A "**Bullish**" stance, indicates that the analyst expects the sector to outperform the Benchmark during the next six months.

A "**Neutral**" stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next six months.

A "**Bearish**" stance, indicates that the analyst expects the sector to underperform the Benchmark during the next six months.

Benchmarks are as follows: **Japan:** TOPIX; **United States:** S&P 500, MSCI World Technology Hardware & Equipment; **Europe**, by sector — *Hardware/Semiconductors:* FTSE W Europe IT Hardware; *Telecoms:* FTSE W Europe Business Services; *Business Services:* FTSE W Europe; *Auto & Components:* FTSE W Europe Auto & Parts; *Communications equipment:* FTSE W Europe IT Hardware; **Ecology Focus:** Bloomberg World Energy Alternate Sources; **Global Emerging Markets:** MSCI Emerging Markets ex-Asia.

Explanation of Nomura's equity research rating system for Asian companies under coverage ex Japan published prior to 30 October 2008:

Stocks:

Stock recommendations are based on absolute valuation upside (downside), which is defined as (Fair Value - Current Price)/Current Price, subject to limited management discretion. In most cases, the Fair Value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as Discounted Cash Flow or Multiple analysis etc. However, if the analyst doesn't think the market will revalue the stock over the specified time horizon due to a lack of events or catalysts, then the fair value may differ from the intrinsic fair value. In most cases, therefore, our recommendation is an assessment of the difference between current market price and our estimate of current intrinsic fair value. Recommendations are set with a 6-12 month horizon unless specified otherwise. Accordingly, within this horizon, price volatility may cause the actual upside or downside based on the prevailing market price to differ from the upside or downside implied by the recommendation.

- A rating of "1", or "**Strong buy**" recommendation indicates that upside is more than 20%.
- A rating of "2", or "**Buy**" recommendation indicates that upside is between 10% and 20%.
- A rating of "3", or "**Neutral**" recommendation indicates that upside or downside is less than 10%.
- A rating of "4", or "**Reduce**" recommendation indicates that downside is between 10% and 20%.
- A rating of "5", or "**Sell**" recommendation indicates that downside is more than 20%.

Sectors:

A "**Bullish**" rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation.

A "**Neutral**" rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation.

A "**Bearish**" rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation.

Price targets

Price targets, if discussed, reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market, and may not occur if the company's earnings differ from estimates.

DISCLAIMERS

This publication contains material that has been prepared by the Nomura entity identified on the banner at the top or the bottom of page 1 herein and, if applicable, with the contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or elsewhere identified in the publication. Affiliates and subsidiaries of Nomura Holdings, Inc. (collectively, the "Nomura Group"), include: Nomura Securities Co., Ltd. ("NSC") Tokyo, Japan; Nomura International plc, United Kingdom; Nomura Securities International, Inc. ("NSI"), New York, NY; Nomura International (Hong Kong) Ltd., Hong Kong; Nomura Singapore Ltd., Singapore; Nomura Australia Ltd., Australia; P.T. Nomura Indonesia, Indonesia; Nomura Securities Malaysia Sdn. Bhd., Malaysia; Nomura International (Hong Kong) Ltd., Taipei Branch, Taiwan; Nomura International (Hong Kong) Ltd., Seoul Branch, Korea; or Nomura Financial Advisory and Securities (India) Private Limited, Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai – 400 018, India; SEBI Registration No:- BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034).

This material is: (i) for your private information, and we are not soliciting any action based upon it; (ii) not to be construed as an offer to sell or a solicitation of an offer to buy any security in any jurisdiction where such offer or solicitation would be illegal; and (iii) based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such.

Opinions expressed are current opinions as of the original publication date appearing on this material only and the information, including the opinions contained herein, are subject to change without notice. If and as applicable, NSI's investment banking relationships, investment banking and non-investment banking compensation and securities ownership (identified in this report as "Disclosures Required in the United States"), if any, are specified in disclaimers and related disclosures in this report. In addition, other members of the Nomura Group may from time to time perform investment banking or other services (including acting as advisor, manager or lender) for, or solicit investment banking or other business from, companies mentioned herein. Further, the Nomura Group, and/or its officers, directors and employees, including persons, without limitation, involved in the preparation or issuance of this material may, to the extent permitted by applicable law and/or regulation, have long or short positions in, and buy or sell, the securities (including ownership by NSI, referenced above), or derivatives (including options) thereof, of companies mentioned herein, or related securities or derivatives. In addition, the Nomura Group, excluding NSI, may act as a market maker and principal, willing to buy and sell certain of the securities of companies mentioned herein. Further, the Nomura Group may buy and sell certain of the securities of companies mentioned herein, as agent for its clients.

Investors should consider this report as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision.

NSC and other non-US members of the Nomura Group (i.e., excluding NSI), their officers, directors and employees may, to the extent it relates to non-US issuers and is permitted by applicable law, have acted upon or used this material prior to, or immediately following, its publication.

Foreign currency-denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk.

The securities described herein may not have been registered under the U.S. Securities Act of 1933, and, in such case, may not be offered or sold in the United States or to U.S. persons unless they have been registered under such Act, or except in compliance with an exemption from the registration requirements of such Act. Unless governing law permits otherwise, you must contact a Nomura entity in your home jurisdiction if you want to use our services in effecting a transaction in the securities mentioned in this material.

This publication has been approved for distribution in the United Kingdom and European Union as investment research by Nomura International plc ("NIPIC"), which is authorised and regulated by the U.K. Financial Services Authority ("FSA") and is a member of the London Stock Exchange. It does not constitute a personal recommendation, as defined by the FSA, or take into account the particular investment objectives, financial situations, or needs of individual investors. It is intended only for investors who are "eligible counterparties" or "professional clients" as defined by the FSA, and may not, therefore, be redistributed to retail clients as defined by the FSA. This publication may be distributed in Germany via Nomura Bank (Deutschland) GmbH, which is authorised and regulated in Germany by the Federal Financial Supervisory Authority ("BaFin"). This publication has been approved by Nomura International (Hong Kong) Ltd. ("NIHK"), which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. Neither NIPIC nor NIHK hold an Australian financial services license as both are exempt from the requirement to hold this license in respect of the financial services either provides. This publication has also been approved for distribution in Malaysia by Nomura Securities Malaysia Sdn. Bhd. In Singapore, this publication has been distributed by Nomura Singapore Limited ("NSL"). NSL accepts legal responsibility for the content of this publication, where it concerns securities, futures and foreign exchange, issued by its foreign affiliate in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this publication may contact NSL in respect of matters arising from, or in connection with, this publication. NSI accepts responsibility for the contents of this material when distributed in the United States.

No part of this material may be (i) copied, photocopied, or duplicated in any form, by any means, or (ii) redistributed without the prior written consent of the Nomura Group member identified in the banner on page 1 of this report. Further information on any of the securities mentioned herein may be obtained upon request. If this publication has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this publication, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Additional information available upon request.

NIPIC and other Nomura Group entities manage conflicts identified through the following: their Chinese Wall, confidentiality and independence policies, maintenance of a Stop List and a Watch List, personal account dealing rules, policies and procedures for managing conflicts of interest arising from the allocation and pricing of securities and impartial investment research and disclosure to clients via client documentation.

Disclosure information is available at the Nomura Disclosure web page: <http://www.nomura.com/research>

Nomura Financial Advisory and Securities (India) Private Limited
Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road,
Worli, Mumbai- 400 018, India

Tel: +91 22 4037 4037

Fax: +91 22 4037 4111

Caring for the environment: to receive only the electronic versions of our research, please contact your sales representative.